These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2867862)
21. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943 [TBL] [Abstract][Full Text] [Related]
22. [Side effects of azulfidine therapy]. Miller B Med Welt; 1976 Jul; 27(27):1334-5. PubMed ID: 8688 [No Abstract] [Full Text] [Related]
23. Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine. Goenka MK; Kochhar R; Tandia B; Mehta SK Am J Gastroenterol; 1996 May; 91(5):917-21. PubMed ID: 8633581 [TBL] [Abstract][Full Text] [Related]
24. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Hanauer SB; Stathopoulos G Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590 [TBL] [Abstract][Full Text] [Related]
25. Sulfasalazine and folate deficiency. Spindel E JAMA; 1983 Aug; 250(7):900. PubMed ID: 6134849 [No Abstract] [Full Text] [Related]
26. Sulfasalazine therapy in inflammatory bowel disease. Das KM Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989 [TBL] [Abstract][Full Text] [Related]
27. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis. Molnár T; Farkas K; Nagy F; Iványi B; Wittmann T Inflamm Bowel Dis; 2010 Apr; 16(4):552-3. PubMed ID: 19637363 [No Abstract] [Full Text] [Related]
28. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Rubin R Am J Gastroenterol; 1994 May; 89(5):789-91. PubMed ID: 7909645 [TBL] [Abstract][Full Text] [Related]
29. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. Tremblay L; Pineton de Chambrun G; De Vroey B; Lavogiez C; Delaporte E; Colombel JF; Cortot A J Crohns Colitis; 2011 Oct; 5(5):457-60. PubMed ID: 21939920 [TBL] [Abstract][Full Text] [Related]
30. Comparative tolerability of therapies for ulcerative colitis. Ardizzone S; Bianchi Porro G Drug Saf; 2002; 25(8):561-82. PubMed ID: 12113642 [TBL] [Abstract][Full Text] [Related]
37. Current status of drug therapy for inflammatory bowel disease. Peppercorn MA Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866 [TBL] [Abstract][Full Text] [Related]
39. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
40. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]